Revolutionizing spinal fusion and fracture fixation through advanced biomaterials

PRODUCTS

XERAFUSE

Xerafuse™ is Moroxite’s bone mineral granule, a ceramic that can be impregnated with bone morphogenetic protein-2 (BMP-2) during surgery for successful spinal fusion.

Xerafuse has the potential to replace autograft transplantation with a lower and safer BMP-2 dose than used in available carriers and technology.

Xerafuse BMP is in late preclinical stage with clinical studies being planned.

Xerafuse can also be used as a standalone bone substitute and graft extender without BMP-2.

XERAFILL

Xerafill™ HA/CaS injectable bone substitute is used in a novel fixation method to reduce the risk of re-operation in fragility fractures.

Moroxite’s Xerafill is delivered at the interface between metallic screw and the adjacent fragile bone. Studies indicate an immediate improved screw bone anchorage. and a reduced risk of late fixation failure and re-operation.

Xerafill is in development phase with ongoing preparations for FDA clearance.

Future development will focus on targeting and activating the bone substitute with a systemic bone active drug, a bisphosphonate, to increase new bone formation.

NEWS AND PUBLICATIONS

Important milestone - funding secured

Moroxite AB has successfully raised SEK 22 million— backed by current owners and a small number of selected new investors. This funding...

News

2 days ago

Moroxite advances to stage 2 of European Innovation Council's Accelerator Programme with Xerafuse™

Moroxite has successfully cleared Stage 1 of the EIC Accelerator programme for our innovative product, Xerafuse™. This bone mineral...

News

Apr 8

Exploring an innovative augmentation strategy in spinal fusion: A novel selective prostaglandin EP4 receptor agonist as a potential osteopromotive factor to enhance lumbar posterolateral fusion

Background On-site delivery of bioactive agents facilitates enhancing the effectiveness of spinal fusion. However, the FDA-approved...

Publications

Jan 14

ABOUT US

We are dedicated to the development of next generation therapeutics in spinal fusion and fracture fixation. We aim to improve patient quality of life and cut societal cost by eliminating the need for autograft in spinal fusion and decrease surgery failure rates.

Our concepts have been developed over decades and are rooted in frontline bone and joint research. Moroxite was founded by Professors of Orthopedics Lars Lidgren and Magnus Tägil as well as PhD Engineer Deepak Raina of Lund University in Sweden.

Moroxite has a well-established and strong patent position covering all important markets and is continually securing IP rights for its unique technology.